GlassScriptPhysician profile
Jessica Purdom
NPI 1932430394
$7,044.20
in general payments reported to CMS, 2019-2025
52 companies · $3,521 in 2025
The $3,521 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $856 · 2023: $1,446 · 2024: $1,223 · 2025: $3,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Honoraria: $980 · Travel and Lodging: $545 · Education: $73.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,589.26 |
| Honoraria | $980.00 |
| Travel and Lodging | $545.42 |
| Education | $73.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,894.81 | 2023-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $660.24 | 2022-2025 | Imfinzi, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $428.66 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $313.07 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $287.60 | 2022-2025 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $257.07 | 2024-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $202.77 | 2023-2025 | |
| Abbvie INC. | $195.65 | 2023-2025 | |
| Lilly USA, LLC | $185.56 | 2022-2025 | Retevmo, Jaypirca, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $157.66 | 2022-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $150.27 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Gen-Probe, INC. | $149.67 | 2023 | Btx |
| Mirati Therapeutics, INC. | $140.58 | 2023-2024 | Krazati |
| Incyte Corporation | $127.75 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Deciphera Pharmaceuticals INC. | $112.85 | 2024-2025 | Qinlock, Romvimza |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $107.85 | 2024-2025 | Trodelvy |
| Genzyme Corporation | $105.51 | 2022-2024 | |
| Astellas Pharma US INC | $97.44 | 2022-2025 | Padcev, Vyloy |
| Adaptive Biotechnologies Corporation | $97.43 | 2022 | |
| Eisai INC. | $95.45 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $86.45 | 2023-2025 | |
| Beigene USA, INC. | $85.96 | 2022-2024 | Brukinsa |
| Pfizer INC. | $82.26 | 2024-2025 | |
| Daiichi Sankyo INC. | $78.43 | 2023-2025 | Enhertu |
| Alexion Pharmaceuticals, INC. | $69.78 | 2024-2025 | Ultomiris |
| Stemline Therapeutics INC. | $60.52 | 2023-2025 | Orserdu |
| Glaxosmithkline, LLC. | $59.77 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Ipsen Biopharmaceuticals, INC | $54.10 | 2024 | Onivyde |
| Sanofi-Aventis U.S. LLC | $52.99 | 2023 | |
| Hologic Sales and Service, LLC | $49.42 | 2024-2025 | Aptima |
| Genentech USA, INC. | $46.48 | 2024 | Polivy, Columvi, Lunsumio |
| Bayer Healthcare Pharmaceuticals INC. | $46.40 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $42.91 | 2025 | |
| Seagen INC. | $41.87 | 2023 | Padcev, Tukysa |
| Puma Biotechnology, INC. | $41.84 | 2025 | |
| Beone Medicines USA, INC. | $40.08 | 2025 | Tevimbra, Brukinsa |
| Springworks Therapeutics, INC. | $33.96 | 2024 | Ogsiveo |
| Sun Pharmaceutical Industries INC. | $32.34 | 2024-2025 | |
| Taiho Oncology, INC. | $29.07 | 2025 | |
| Genmab U.S., INC. | $25.80 | 2025 | Epkinly |
| G1 Therapeutics, INC. | $24.03 | 2023 | Cosela |
| Array Biopharma INC | $23.95 | 2022 | |
| Secura Bio, INC. | $19.37 | 2024 | Copiktra |
| Sumitomo Pharma America, INC. | $18.56 | 2024 | Orgovyx |
| Fennec Pharmaceuticals, INC. | $18.54 | 2025 | Fyarro |
| Geron Corporation | $18.50 | 2025 | Rytelo |
| Sobi, INC | $17.65 | 2025 | |
| Servier Pharmaceuticals LLC | $16.92 | 2024 | |
| Coherus Oncology, INC. | $16.47 | 2025 | Loqtorzi |
| Amgen INC. | $15.37 | 2023 | Vectibix, Xgeva, Nplate |
| Tersera Therapeutics LLC | $13.65 | 2024 | Xermelo |
| Cti Biopharma Corp. | $12.87 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Purdom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.